This partnership aims to revolutionize the understanding and treatment of various tremor conditions, using the combined expertise of both organizations in medical analysis and device development.
The collaboration is framed as a ‘know-how’ agreement, wherein the two entities will pool their respective strengths to delve into Parkinson’s tremors, functional tremors (FT), and essential tremors (ET). This initiative holds the promise of pioneering advancements in treating these conditions through AI-driven digital therapeutics.
A significant focus of the study will be on functional tremors, which are notoriously difficult to treat due to their requirement for specialized therapy over medication. Current treatment options are limited, often necessitating patients to take substantial time off from work or school.
Difficult to treat functional tremors
“Our experience in assisting patients with various forms of tremors has been highly encouraging. We hope this collaborative study will yield significant results that corroborate our previous findings and help broaden treatment options,” said Gary Krasilovsky, PhD, Chief Scientific Officer of JOGO Health. Krasilovsky brings over four decades of experience in neuroplasticity research to this groundbreaking study.
JOGO Health’s CEO, Sanjai Murali, highlighted the potential impact of this collaboration on patient lives, stating, “I’m excited about the confluence of Mayo Clinic’s expertise in tremors and JOGO’s expertise in EMG biofeedback modality to develop specialized treatments for tremors. This has the potential to help millions of patients who do not have effective treatment options.”
JOGO Health’s proprietary non-invasive digital therapeutic device, JOGO-Gx, integrates AI and wearable technology, showing early success in treating Parkinson’s Disease. The upcoming study, slated to commence in September 2024, will run for one year, assessing the efficacy of this innovative approach and guiding further device development.
Non-invasive digital therapeutic device
The study aims to scrutinize the effectiveness of AI-driven digital therapeutics in treating tremors that significantly impact the quality of life for individuals with Parkinson’s, FT, and ET. By doing so, JOGO Health and Mayo Clinic aspire to expand the range of viable treatment options, making specialized therapy more accessible and less disruptive to patients’ daily lives.
“It’s an honor to work with Mayo Clinic and its resources for tremor expertise,” said Murali. “JOGO’s proficiency in EMG biofeedback has the potential to help millions of patients who have not been able to find effective treatment options for their debilitating conditions.”
Mayo Clinic, which has a financial interest in the technology referenced in this press release, will utilize any revenue received from this collaboration to support its not-for-profit mission in patient care, education, and research.
JOGO Health and Mayo Clinic – groundbreaking solutions
JOGO Health is a digital therapeutics company founded after over nine years of rigorous research and testing. Building on the pioneering work of the late Dr Joe Brudny of New York University’s Rusk Rehabilitation Center and Dr Gordon Silverman of Rockefeller University, JOGO utilizes wearable sensors and an AI-driven app to treat chronic pain, Parkinson’s tremors, and other movement disorders associated with neurological conditions via telemedicine.
The new clinical trial between JOGO Health and Mayo Clinic seeks to offer groundbreaking solutions for people with functional tremors, a condition that currently requires specialized therapy instead of medication. Through this study, both entities hope to develop AI-driven digital therapeutics that can transform the treatment landscape for tremors, offering new hope to millions of patients worldwide.